Selective endothelin receptor blockade in resistant hypertension: results of the DORADO trial

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.1, 2011-01, pp. : 153-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Endothelin receptor blockade attenuates air embolization-induced pulmonary hypertension in sheep

By Miyahara T. Koizumi T. Kubo K. Hanaoka M. Kaneki T. Yamamoto H. Ge R.-L. Fujimoto K. Kobayashi T. Shibamoto T.

European Journal of Pharmacology, Vol. 385, Iss. 2, 1999-12 ,pp. : 163-169

Elsevier

Access to resources Recommend Favorite

Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

By Horn Evelyn M Widlitz Allison C Barst Robyn J

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1483-1492

Informa Healthcare

Access to resources Recommend Favorite

Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension

By O'Callaghan Dermot S Savale Laurent Yaïïci Azzedine Natali Delphine Jaïïs Xavier Parent Florence Montani David Humbert Marc Simonneau Géérald Sitbon Olivier

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1585-1596

Informa Healthcare

Access to resources Recommend Favorite

An update on the status of endothelin receptor antagonists for hypertension

By Dao Huy Hao Moreau Pierre

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 11, 2001-11 ,pp. : 1937-1946

Informa Healthcare

Access to resources Recommend Favorite

EARTH: Endothelin_A Receptor Antagonist Trial in Heart Failure

Heart Drug, Vol. 1, Iss. 6, 2002-02 ,pp. : 294-298

Karger

Access to resources Recommend Favorite